Lilly's orforglipron pill goes on sale in Britain, its first market outside the US

Foundayo is now available by private prescription in Britain, giving eligible adults a second oral GLP-1 option outside the NHS.

Britain is the first country in Europe where the tablet is available to patients. For now it is sold only by private prescription. It is the second GLP-1 pill to reach British pharmacies, after Novo Nordisk's oral Wegovy, which arrived in July.

The launch follows the regulator's decision two weeks earlier. The Medicines and Healthcare products Regulatory Agency authorised orforglipron on August 10, 2026.

The weight-management approval covers adults with a body mass index of at least 30. It also covers adults with a BMI from 27 to 29.9 and at least one weight-related health condition. Patients also receive guidance on eating fewer calories and increasing physical activity.

The same authorisation covers blood sugar control in adults with inadequately controlled type 2 diabetes. Eli Lilly holds the UK marketing authorisation.

The practical selling point is how the pill is taken. The MHRA says the once-daily tablet has no food or water restrictions. Oral semaglutide requires an empty stomach, a small amount of water, and a wait before eating.

Price and NHS access remain open questions. Reuters-sourced coverage put the likely private cost at about £100 to £120 per month. The same report put Mounjaro at about £330 per month. Private providers set their own prices, so these figures are not a single national price.

Foundayo is not available on the NHS. The National Institute for Health and Care Excellence, or NICE, must assess it first. NICE asked for more information after its first committee meeting and has not scheduled a second one. Lilly said it is working with NICE during the review.

Foundayo changes the tradeoffs of oral treatment

Eligible adults in the UK now have a second oral GLP-1 option through private care. A prescriber still decides whether the medicine fits the approved criteria. The launch does not change NHS eligibility.

Reported prices come from private providers, not a national price list. A pharmacy or online clinic can charge outside that range. Prices can also change as more suppliers stock the medicine.

For readers outside Britain, the launch matters mainly as a supply signal. Foundayo was approved in the United States in April 2026. Orforglipron is made as a chemical tablet rather than a peptide injection. It does not need refrigerated shipping, injector pens, or the sterile factories used to fill injectable drugs. Analysts therefore expect oral GLP-1 medicines to scale differently from injections. The launch does not show that this difference will lower prices in any market.

Foundayo was not compared directly with injections

Regulators did not compare orforglipron directly with tirzepatide or injectable semaglutide. The approval relied on trials against placebo, an inactive treatment used for comparison. Weight-loss results from separate trials involve different people and study rules, so they do not prove which drug works better.

The MHRA lists nausea, constipation, and diarrhoea among common side effects. Patients and clinicians can report suspected reactions through the Yellow Card scheme. NICE has not decided on NHS coverage, and private availability does not predict that decision.